PDCD1 and hepatocellular carcinoma: Similarly, sintilimumab (anti-PD-1) plus IBI305 (bevacizumab biosimilar) improved survival rates compared to sorafenib in Chinese patients with unresectable, hepatitis B virus (HBV)- associated HCC (13).